Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Arctic Bioscience AS ( (DE:9TD) ).
Arctic Bioscience reported encouraging results from the HeROPA study, highlighting significant progress in their pharmaceutical and dietary supplement sectors. The company secured NOK 30 million in financing, launched a new skincare product, and reduced operational costs significantly. Despite challenges in the dietary supplement business due to a recall, revenue and margins improved, and the company plans to expand its skincare product internationally. The positive development in Arctic Algae and the strategic focus on expanding B2C business and cost management are expected to strengthen their market position.
More about Arctic Bioscience AS
Arctic Bioscience is a biotechnology company that develops and commercializes pharmaceutical products and dietary supplements based on unique bioactive marine raw materials. The company is developing HRO350, a new oral drug candidate for the treatment of mild-to-moderate psoriasis. Their dietary supplements are sold globally under the ROMEGA® brand.
Average Trading Volume: 76,266
Current Market Cap: NOK110.4M
For detailed information about 9TD stock, go to TipRanks’ Stock Analysis page.